RE:RE:VolumeONC was the 3rd largest % gainer today on the TSX at 20%.
ONC was the 21st biggest % gainer today on the Nasdaq at 19.8%
That will draw attention to ONC/ONCY just by that those biggest % gainer charts, and with more promising news and expansion of disucssions coming throughout the next week leading up to the Key Opinion Leaders (KOL) discussion on Nov 14th, I am expecting a steady SP climb through to and beyond Nov 14th.
We need new interested investors as trading for the past many months has been balanced and flat, so this biggest % gainers attention is another step in the right direction to attract new investors.
I am also expecting that we will see upgraded SP target prices soon. TD bank was $3 CDN, I expect that will be upgraded. The other target prices of $12 and $15 were only for a single Phase III trial of mBC, so I expect we will see upgrades there too, to include the second Phase III Gastro side. Although, they may not spend the time to upgrade them until after they have heard the full data/discussion presentations of information extending out to Nov 14th. But, we should be seeing upgraded SP target prices soon after Nov 14th, and possibly other anyalysts starting to cover ONC. Wouldn't that be nice!
The fact that the Dr. running the Goblet Trial stated publicly that in his opinion "pelareorep will transform the standard of care" for pancriatic is huge, and WILL NOT go unnoticed. I think we will be hearing more of these kinds of comments through to Nov 14th.
I have no access to the current SHORTS numbers, so I have no idea if shorts will come into play and help boost daily gains, but I hope they are all covered, or covered soon. Yahoo shows 163,530 shorts as of Oct 14th, 2022. That is not a lot, and I do not know what price points they were shorted at, and could be possibly as high as the $5-$6 range. If ONC continues to trade around 400K 500K shares daily there should be no significant short squeeze IMHO.
Two (2) Phase III registristration studies bascially confirmed as of today.
It would appear that we are truly entering a new era for ONC.